Galderma
Galderma, a leading global pharmaceutical company dedicated exclusively to the field of dermatology, signed a collaboration and licensing agreement with NovaBay in March 2009. Galderma and NovaBay are working together to research, develop and commercialize NovaBay’s Aganocide compounds to treat all major dermatological conditions, excluding onychomycosis (nail fungus).
December 6, 2010
NovaBay Pharmaceuticals, Inc. and Galderma Expand Their Agreement to Include Impetigo
